Comparative Pharmacology
Head-to-head clinical analysis: PIMOZIDE versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIMOZIDE versus THORAZINE.
PIMOZIDE vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks dopamine D2, D3, and D4 receptors; also 5-HT2A, α1-adrenergic, and H1 receptors.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
1-10 mg orally once daily; maximum 10 mg/day.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 50-60 hours in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Clinical Note
moderatePimozide + Levofloxacin
"Pimozide may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderatePimozide + Norfloxacin
"Pimozide may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderatePimozide + Gemifloxacin
"Pimozide may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderatePimozide + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Pimozide is combined with Fluticasone propionate."
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 70-90% of eliminated drug; fecal excretion ~10-30%.
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic